The historical rank and industry rank for Arbutus Biopharma's Days Payable or its related term are showing as below:
ABUS's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Arbutus Biopharma's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Arbutus Biopharma Days Payable Related Terms
Arbutus Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arbutus Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arbutus Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #999999 out of 707 companies in the Biotechnology industry.
Is Arbutus Biopharma's Days Payable too high?
Arbutus Biopharma's current Days Payable is 0.00. Based on the distribution chart, Arbutus Biopharma ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Days Payable compare to SPRY and KURA?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #999999 out of 707 companies for Days Payable. This places Arbutus Biopharma in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.39, compared to a current price of $4.48 — trading 91.3% below its estimated fair value. The current Days Payable is 0.00. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.48 is trading 91.3% below its estimated GF Value™ of $51.39.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Days Payable: 0.00
GF Value™: $51.39 vs. price of $4.48 (91.3% below fair value)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for ABUS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
